DeepMed Research

ANRS, Emerging Infectious Diseases

🇫🇷France

Country: 🇫🇷France

Ownership: Private

Employees: -

Market Cap: -

Website

Clinical Trials

A Study to Determine the Cartography of Virologic Reservoir Related to Antiretroviral Concentrations in HIV-1 Chronic Patients Treated by a First Line Treatment Containing Bictégravir, Emtricitabine and Ténofovir Alafénamide

Not Applicable

Not yet recruiting

Conditions: HIV-1-infection

Interventions: Other: Biopsies and bloood samplings

First Posted Date: 2022-02-03

Last Posted Date: 2025-02-05

Lead Sponsor: ANRS, Emerging Infectious Diseases

Target Recruit Count: 34

Registration Number: NCT05222945

Locations: 🇫🇷
Antoine-Beclere Hospita, Clamart, France
🇫🇷
Hotel Dieu Hospital, Paris, France
🇫🇷
Necker Hospital, Paris, France

and more 3 locations

Pre-exposure Prophylaxis of SARS-CoV-2 Infection (COVID-19) by Monoclonal Antibodies with Early Access Authorization in Immunocompromised Patients. a Prospective Cohort.

Completed

Conditions: Immunocompromised Host
COVID-19

First Posted Date: 2022-01-31

Last Posted Date: 2025-01-29

Lead Sponsor: ANRS, Emerging Infectious Diseases

Target Recruit Count: 149

Registration Number: NCT05216588

Locations: 🇫🇷
Hôpital Avicenne, Bobigny, France

Pilot Study Evaluating the Impact of Delay Between Administration of Inmazeb Administration and Vaccination by Ervebo on Vaccine Immune Response on Healthy Volunteers

Phase 2

Conditions: Ebola Virus Disease

Interventions: Biological: Ervebo
Drug: Inmazeb

First Posted Date: 2022-01-21

Last Posted Date: 2022-01-21

Lead Sponsor: ANRS, Emerging Infectious Diseases

Target Recruit Count: 135

Registration Number: NCT05202288

Locations: 🇬🇳
Research center of Landreah, Conakry, Guinea

ANRS HB07 IP-Cure-B Proof of Concept (PoC) Clinical Trial. Educating the Liver Immune Environment Through TLR8 Stimulation Followed by NUC Discontinuation

Phase 2

Conditions: Hepatitis B, Chronic

Interventions: Drug: administration of SLGN in arm C
Drug: Discontinuation of NUC treatment in arms B and C

First Posted Date: 2021-09-16

Last Posted Date: 2022-03-14

Lead Sponsor: ANRS, Emerging Infectious Diseases

Target Recruit Count: 100

Registration Number: NCT05045261

Locations: 🇫🇷
Hepato-gastroenterology department, Hôpital Saint-Joseph, Marseille, France
🇮🇹
Gastroenterology and Hepatology Division, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan, Italy
🇫🇷
Hepatology Department, Hospices Civils de Lyon, Lyon, France

and more 5 locations

Prevention of Mental Health Problems Among Persons Without Personal Housing in the Context of the COVID-19 Epidemic

Not Applicable

Conditions: Quality of Life
Psychosocial Intervention
Psychological Distress

Interventions: Behavioral: Psychological First Aid (PFA)
Behavioral: Care as Usual (CAU)
Behavioral: Doing What Matters in Times of Stress (DWM)
Behavioral: Problem Management Plus (PM+)

First Posted Date: 2021-09-02

Last Posted Date: 2022-07-25

Lead Sponsor: ANRS, Emerging Infectious Diseases

Target Recruit Count: 210

Registration Number: NCT05033210

Locations: 🇫🇷
CAPSYS, Paris, Île De France, France
🇫🇷
Normandy Psychotrauma Center, Caen, Normandie, France

Evaluation of Measurement of Maternal Viral Load at Delivery to Optimise Post-natal Prophylaxis of HIV-exposed Newborns

Conditions: Mother to Child HIV Transmission

Interventions: Diagnostic Test: point of care

First Posted Date: 2021-08-24

Last Posted Date: 2022-02-16

Lead Sponsor: ANRS, Emerging Infectious Diseases

Target Recruit Count: 100

Registration Number: NCT05017558

Partner Notification of Sexually Transmitted Infections (STIs) in Testing Centers

Conditions: Hiv
STI

Interventions: Other: 2 online self-administered questionnaires on

First Posted Date: 2021-06-10

Last Posted Date: 2022-07-25

Lead Sponsor: ANRS, Emerging Infectious Diseases

Target Recruit Count: 2200

Registration Number: NCT04921618

Locations: 🇫🇷
CeGIDD d'Aix-en-Provence, Aix-en-Provence, France
🇫🇷
CeGIDD - Saint Adrien, Marseille, France
🇫🇷
CeGIDD de Lille, Lille, France

and more 6 locations

Early Treatment of Vulnerable Individuals With Non-Severe SARS-CoV-2 Infection

Phase 2

Conditions: Covid19
Covid19 Drug Treatment
SARS-CoV2 Infection
Severe Acute Respiratory Syndrome Coronavirus 2

Interventions: Drug: Nitazoxanide and Ciclésonide
Drug: Telmisartan 20Mg Oral Tablet
Drug: Fluoxétine and Budésonide
Drug: Paracetamol

First Posted Date: 2021-06-10

Last Posted Date: 2023-01-31

Lead Sponsor: ANRS, Emerging Infectious Diseases

Target Recruit Count: 600

Registration Number: NCT04920838

Locations: 🇬🇳
Centre de traitement des maladies à tendance épidémique de Gbessia, Conakry, Guinea
🇧🇫
Centre Muraz/INSP, Bobo-Dioulasso, Burkina Faso

Prevalence and Longitudinal Follow-up of Anal Lesions, HPV Infection and Associated Sexually Transmitted Infections Among Men Who Have Sex With Men in Togo.

Recruiting

Conditions: Papillomavirus Infections
HIV Infections

First Posted Date: 2021-06-02

Last Posted Date: 2022-02-16

Lead Sponsor: ANRS, Emerging Infectious Diseases

Target Recruit Count: 200

Registration Number: NCT04910438

Locations: 🇹🇬
ONG, Espoir Vie Togo, Lomé, Togo

Prevention of COVID-19 Complications in High-risk Subjects Infected by SARS-CoV-2 and Eligible for Treatment Under a Cohort ATU ('Autorisation Temporaire d'Utilisation') OR or Authorisation for Early Access (AAP). A Prospectvie Cohort.

Conditions: SARS-CoV Infection
Covid19

Interventions: Other: biobank

First Posted Date: 2021-05-13

Last Posted Date: 2022-04-13

Lead Sponsor: ANRS, Emerging Infectious Diseases

Target Recruit Count: 2000

Registration Number: NCT04885452

Locations: 🇫🇷
CH Agen-Nerac, Agen, France
🇫🇷
CHU d'Angers, Angers, France
🇫🇷
CHR Metz-Thionville, Ars-Laquenexy, France

and more 34 locations

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy